ZOGENIX, INC.
ZOGENIX, INC. (ZGNX): 7 pipeline candidates · ~22 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.4 months
D/E 1.62 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for ZOGENIX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$101.2M
Quarterly Burn
$41.1M
Runway
22.4 mo
Revenue
$26.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| fenfluramine | Phase 4 |
| fintepla | Phase 4 |
| gene therapies for dravet syndrome | Phase 3 |
| mt-1621 | Phase 2 |
| mt1621 | Phase 2 |
| zx008 | Phase 3 |
| zx008 0.2 or 0.8 mg/kg/day | Phase 3 |
Frequently asked questions
How many drug candidates are in ZOGENIX, INC.'s pipeline?
ZOGENIX, INC. (ZGNX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ZOGENIX, INC.'s lead drug candidate?
ZOGENIX, INC.'s most advanced tracked candidate is fenfluramine (Phase 4) for CDKL5 Deficiency Disorder.
What is ZOGENIX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ZOGENIX, INC. has approximately 22.4 months of cash runway.
Who is the CEO of ZOGENIX, INC.?
Stephen J. Farr, Ph.D. is the chief executive officer of ZOGENIX, INC. (ZGNX).
Get the full picture on ZOGENIX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.